Abstract Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Persistent pain is the most common and distressing symptom of JIA, and pain in childhood arthritis is multifactorial. Children and adolescents with persistent pain due to JIA experience significantly more problems with physical, emotional, social, and school functioning than healthy individuals. Assessment of pain at each office visit is the cornerstone of effective pain management and should include an evaluation of pain intensity, interference, and coping. Following the biopsychosocial model of pain management, a multi-modal approach is recommended for pain control in children with arthritis. Pharmacologic strategies for the treatment of pain in JIA include aggressive treatment of the underlying disease as well as the use of acetaminophen and systemic and topical non-steroidal anti-inflammatory drugs for persistent mild pain. Opioids can be considered in the case of moderate to severe persistent pain. Physical therapies and psychological interventions such as cognitive behavioral therapy are also key components of pain management in JIA.
prevalence of up to one case per 1,000 children [1] . JIA is not a single disease-rather, it is an umbrella diagnosis referring to all types of chronic, idiopathic arthritides with onset before the age of 16 years. Criteria for classification of different JIA subtypes have been developed, with the goal of describing phenotypically distinct groups [2] . JIA subtype is determined by multiple factors, including the number of affected joints, presence of axial arthritis and/or enthesitis, serologic markers, and presence of systemic inflammation and extra-articular disease.
Chronic pain in pediatrics is commonly defined as prolonged pain that lasts longer than 3 months or any recurrent pain that occurs at least three times throughout a period of 3 months. Chronic pain is the most common and distressing symptom of JIA, and children with arthritis experience as much pain as adults [3] [4] [5] [6] . In a diary study of 41 polyarticular JIA patients, Schanberg et al. [7] reported that pain was present on 73 % of all patient days during the 8-week study period, with most patients reporting pain on more than 60 % of days. Thirty-nine percent of patients reported pain on all diary days over the 8-week period, while only 5 % reported no pain over the study period. Seventeen percent of patients were treated with biologic medication. Bromberg et al. [8] reported presence of pain on 66 % of days in an electronic (e)-diary study of 59 patients with JIA. In 31 % of all e-diary entries, the visual analog pain score (VAS) was [40 (range 0-100 mm), indicating moderate to severe pain intensity with 86 % of children reporting a high level of pain at least once during the study period. These results were surprisingly consistent with results from earlier studies, despite the fact that 47 % of patients were treated with a biologic agent. In a survey of North American pediatric rheumatologists, 77 % of respondents agreed that there are patients who continue to experience moderate to severe pain despite appropriately dosed disease-modifying anti-rheumatic drugs (DMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs) [9] . These studies demonstrate that trends toward more prevalent use of biologic medications do not necessarily correlate with trends toward significant pain reduction for patients with JIA. Therefore, pain management for JIA patients remains a highly relevant and pressing concern.
2 Nature of Pain in JIA Pain in JIA is multifactorial. Presence of active arthritis and disease severity contribute to pain but account for a relatively small percentage of the variance in pain severity among patients. Disease severity has been shown to predict from 6.5 to 28 % of the variance in pain [3, 10, 11] . A survey study of 2,571 JIA patients found that predictors of higher pain intensity included higher active joint count and the enthesitis-related arthritis disease subtype [12] . Notably, correlation between physician global assessment (PGA) of disease activity and patient-reported pain intensity was low (0.43, p \ 0.001). Both biologic and psychosocial factors contribute to JIA patients' subjective experience of pain. The influence of age on pain experience is not clear. Results of some studies suggest that younger children may complain of more severe pain [11, 13] while other studies suggest the opposite trend [5, 12, 14] . Chronicity of pain must also be considered, and ongoing pain can result in sensitization of the peripheral and central nervous systems [15] . Several studies have reported reduced pain thresholds and pain tolerance in patients with JIA [16] [17] [18] . Patient pain experience may also be influenced by parental behavior. Protective parent responses may lead to reductions in the child's physical and social activities as well as less positive mood, while distracting parent responses may be associated with positive activity outcomes [19] .
The sequelae of chronic synovitis and its treatment can also contribute to pain, independent of the pain resulting directly from active arthritis. Destruction of articular cartilage is the unfortunate result of chronic synovitis, and it is not uncommon for pediatric patients to have evidence of chondrolysis on radiographic imaging. A recent multi-center, cross-sectional analysis of 4,292 JIA patients demonstrated that 22 % of patients had evidence of joint damage [20] . Such damage can be painful, even under conditions where optimal disease control has been established and synovitis is absent. Localized growth disturbances may result from the effects of arthritis on the growth plate, and the resulting alterations in biomechanics can contribute to chronic pain. Limb length discrepancy and micrognathia are the most common outcomes associated with this phenomenon. Osteopenia may result from synovitis and/ or from chronic corticosteroid treatment, and children with arthritis are at increased risk of fractures as adults and for early onset of osteoporosis [21] [22] [23] . Chronic pain syndromes such as fibromyalgia or complex regional pain syndrome may also occur in children with JIA. These patients may have severe pain, which is often independent of the level of control of their underlying arthritis.
Consequences of Pain in JIA
Pain is known to negatively impact all aspects of healthrelated quality of life (HRQL). JIA patients experience significantly more problems with physical, emotional, social, and school functioning than healthy individuals [24, 25] . Dhanani et al. [26] found that relatively small reductions in pain intensity (0.82 cm on a 10 cm VAS) can result in significant improvements in self-reported quality of life. Problems with gross motor function (walking, running) and systemic symptoms (stiffness, tiredness) frequently contribute to decreased HRQL in patients with JIA [27, 28] .
Pain may limit school attendance and participation in social activities, sports, and physical education [27, 29] . Pain and physical disability have been associated with depression, frustration, and other domains affecting psychosocial HRQL [27, 30, 31] . Increased pain has also been associated with sleep disturbance [32] . A recently published systematic review looking at sleep disturbance found that JIA patients have significantly more sleep disturbances when compared with healthy controls [33] . While pain was often associated with various aspects of sleep disturbances, there was no direct correlation [33] . The lack of association may be due to the different types of sleep difficulties (i.e., frequent wakenings, parasomnias) that occur in all children, regardless of their underlying disease. In contrast, Bromberg et al. [34] have found that children with arthritis and poor quality of sleep, on average, had higher pain intensity scores. More research is needed to clarify the complex relationship between sleep and pain for patients with JIA, as well as other chronic pain disorders.
JIA is a life-long illness with lasting consequences. A long-term follow-up study of adults with JIA revealed that 43 % of patients had clinically active arthritis into adulthood [35] . JIA patients continue to have significantly increased pain and disability as they enter adulthood, with decreased physical function and employment rates compared with healthy controls [35, 36] .
Assessment of Pain
Assessment of pain at each office visit is the cornerstone of effective pain management. In 1996, the American Pain Society established pain as the ''fifth vital sign'' and in 2001, pain assessment was made a requirement for accreditation of hospitals in the United States [37, 38] . More recently, pain control has been identified as a quality measure in the care of children with JIA [37] and should be assessed with age-appropriate, reliable, and valid tools [39] . In the context of assessment, it is critical to consider pain as a multidimensional experience that is comprised of sensory, affective, and evaluative components. The sensory dimension of pain is related to quality (what pain feels like), intensity (how much pain hurts), location (spatial distribution of pain), and duration (how long pain lasts) [40] . The affective dimension is related to the emotional impact of pain, such as the extent to which pain is perceived as unpleasant or distressing. The evaluative dimension describes the degree to which pain is perceived to interfere with physical, psychological, role, and social functioning. Unidimensional pain tools measure one aspect such as pain intensity whereas multidimensional pain tools measure the various dimensions of the pain experience.
Unidimensional Pain Tools
The two common approaches for measurement of pain intensity in children include self-report (what the child says) and behavioral observational measures (how the child behaves). The 100-mm VAS [41, 42] is routinely used for assessing pain intensity for both research and clinical purposes. The VAS is a continuous horizontal line anchored between two variables such as 'no pain' and 'worst pain imaginable'. The VAS is well validated in pediatrics and is recommended for patients aged 8 years and older [43] . The main advantage of the VAS is the ease of both administration and completion by respondents [44] . Numerical self-rating scales (0-10) can also be used with most children over 8 years of age [45] and are often used clinically. Filocamo et al. [46] validated a 21-numbered circle VAS as an alternative to the 10-cm VAS. It was found to be simpler and has the potential advantage of increasing the accuracy of assessment of clinical remission by facilitating incorporation of physician and parent subjective ratings in clinical practice. The authors advised substituting the 10-cm VAS with the 21-numbered circle VAS both in the office setting and in clinical trials. Faces pain scales (FPS) are often used in the pediatric population, and although no gold standard exists, the FPS-revised (FPS-R), which uses a 0-10 metric, can be used in children 4 years of age and older, and correlates closely with the VAS [47] . Verbal rating scales (VRS) use numbers and simple phrases to describe different intensities of pain. Patients are asked to choose the phrase that best represents their pain level, and their score is recorded as the corresponding number. For example, a commonly used VRS is: not at all (0), a little bit (1), quite a lot (2), and most hurt possible (3) [48] . The most common concrete graphic rating scale is called the Pieces of Hurt tool [49] . It consists of four tokens (e.g., poker chips), each representing a different amount of pain, ranging from 'a little hurt' to 'the most hurt you could ever have'. The child is asked to choose the token that represents their level of pain. It is recommended for use in pre-school age children. It is easy to use and score, and the instructions have been translated from English into several languages [50, 51] . The change in a child's pain score is more important than the number itself. A change in pain of 2 out of 10 (i.e., a change of one face using FPS-R) represents the least change that can be considered clinically significant when using a faces scale [52] . Behavioral observation scales, such as the facial expression, leg movement, activity, cry, consolability (FLACC) scale are required for those unable to provide a self-report or when the practitioner thinks the child may be under-reporting pain [53] . It is simple for clinicians to use, score, and interpret [54] .
Multidimensional Pain Tools
There are a limited number of self-report pain scales that assess multiple dimensions of pain (i.e., beyond intensity). The Pediatric Pain Questionnaire (PPQ), modeled after the McGill Pain Questionnaire [55] , is the most commonly used multidimensional tool in JIA. The PPQ uses a 100-mm horizontal VAS anchored with happy and sad faces to assess present pain intensity and worst pain intensity in the past week [56] . Patients are also asked to choose from a list of 46 word descriptors to express sensory (e.g., cutting), affective (e.g., horrible), and evaluative (e.g., sad) qualities of their pain. Pain location is recorded by asking the patient to color in painful regions on anterior and posterior aspects of a gender-neutral outline of the body. The PPQ is intended for use in patients aged 5-18 years and takes 10-15 minutes to complete. There are different versions of the PPQ for children, adolescents, and parents. The PPQ has been translated into multiple languages and has well established evidence of validity [56] .
Advances in technology with the use of Internet and mobile devices have led to real time data collection resulting in improved pain assessment. E-diaries have allowed examination of differences in the children's reported symptoms across mornings, afternoons, and evenings which is important since JIA patients often experience changes in their pain over the course of a single day, such as exacerbated pain during the morning or after periods of inactivity due to joint stiffness [8, 57, 58] . E-diaries can be used to capture pain at each clinic visit or to identify trends and possible triggers in children with more persistent pain in order to tailor pain management interventions [8, 59] . These tools have varying degrees of reliability and validity.
Some examples of e-diaries developed for JIA patients include the e-Ouch multidimensional pain diary for adolescents with arthritis [60] , the Standardized Universal Pain Evaluations for Pediatric Rheumatology Providers (SUPER-KIDZ) pain assessment tool [61] and the Pain-QuILT TM [62] . The e-Ouch diary obtains ratings on pain intensity, unpleasantness, and interference and perceived control over pain [60] . There is a body map (on which pain locations can be selected), word descriptors and questions related to medications and other physical and psychological treatments used and the effectiveness of these strategies. The e-Ouch diary has been shown to be a valid and responsive assessment modality [63] it has only been used in clinical research.
SUPER-KIDZ assesses pain in pediatric patients with rheumatic diseases [64] . It consists of developmentally appropriate self-report measures for patients 8-18 years of age (pain intensity, location, pain impact on physical and emotional functioning) and a truncated version developed for use by children 4-7 years of age (pain intensity and location) [61] . It is easy to use and has face, content, and construct validity, as well as reliability [61] .
Pain-QuILT TM (previously called the iconic pain assessment tool) is a web-and mobile-based tool for the visual self-report and electronic tracking of sensory pain [62] . Patients choose from a library of pain quality 'icons' to express different types of pain, such as a 'matchstick' for 'burning pain'. Descriptive icons can be assigned a rating of intensity (0-10 numerical rating scale) and then dragged-and-dropped onto a virtual body map to show pain location. Pain parameters can track changes in pain over time. Studies in adolescents with chronic pain, including arthritis, indicate that Pain-QuILT TM is easy to use and understand, preferred by a majority of patients, and perceived to improve the communication of pain symptoms with healthcare providers. A free version of the tool is available at http://painquilt.mcmaster.ca.
Management of Pain in JIA
Following the biopsychosocial model of pain management, a multi-modal approach is recommended for pain control in children with arthritis (Table 1) . Management includes early and aggressive treatment of the underlying joint inflammation, combined with additional pharmacological, physical, and psychological therapies to target pain and pain coping, improve physical function, and promote normal growth and development.
Pharmacological Treatment of Pain
To date, there have been no clinical trials that specifically address pharmacological pain management in patients with JIA. However, in addition to improving disease activity, various medical therapies for JIA have also been shown to reduce reported pain and improve HRQL in JIA patients. NSAIDs are often used as first-line or adjunctive therapy in all subtypes of JIA ( Table 2) . As of 2005, the non-selective (ns) NSAIDs that inhibit both cyclooxygenase (COX)-1 and -2 enzymes approved for the treatment of JIA by the US Food and Drug Administration (FDA) included aspirin, naproxen, ibuprofen, tolmetin, indomethacin, and meloxicam [65] . Aspirin is no longer used in clinical practice due to concerns regarding Reye syndrome. Early studies of naproxen in children with JIA showed statistically significant improvement in pain sustained over a 6-month period [66] ; doses up to 10 mg/kg twice daily are recommended with relatively infrequent and mild side effects [66, 67] . Several selective COX-2 inhibitors have also been used effectively in JIA. In December 2006, the FDA approved celecoxib (Pfizer) to treat the signs and symptoms of JIA in children aged 2-17 years [68] . In addition, relatively selective COX-2 inhibitors meloxicam and nabumetone have the benefit of once-daily dosing and have been found to be effective and safe in this population [69, 70] . The choice of NSAID may be based on the taste of the medication, ease of dosing regimen, or availability of a liquid preparation [71] . Although gastrointestinal side effects are rare in patients with JIA, selective COX-2 inhibitors may be of value in a select population. Interestingly, a recent electronic pain diary study by Bromberg et al. [8] showed that children regularly scheduled to take NSAIDs had significantly lower fatigue intensity scores compared with children not taking NSAIDs, regardless of the other drugs they were taking.
Systemic and intra-articular corticosteroids are also often used as bridging and/or adjunctive therapies in JIA. One study found that use of systemic corticosteroids resulted in a greater reduction in pain scores when compared with NSAIDs; however, their use must be weighed against a greater risk of side effects (e.g., weight gain, growth disturbance, osteoporosis, etc) [72] . Thus, the use of systemic corticosteroids to reduce disease activity and pain should be actively discouraged, except in cases of acute flare, severe or uncontrollable disease [73] . Intraarticular corticosteroid injections are generally effective in reducing joint inflammation and are commonly used to treat oligoarticular JIA or as adjunctive treatment in polyarticular-course disease. One study showed a reduction in pain from 26 to 11-mm after injection (on 100-mm VAS) [74] . However, this benefit has not been consistently shown in other studies [75] . A non-invasive alternative to joint injections is dexamethasone iontophoresis (DIP), which involves transdermal delivery of dexamethasone using lowgrade electric currents. One pediatric study of DIP in pediatric patients with temporomandibular joint arthritis resulted in resolution of pain in 73 % of subjects, as well as improved range of motion [76] .
Beyond NSAIDs and corticosteroids, recommended treatments for JIA include non-biologic DMARDs (e.g., Adapted with permission from Kimura and Walco [73] ER extended release, JIA juvenile idiopathic arthritis, NSAIDs non-steroidal anti-inflammatory drugs a Not approved by the US Food and Drug Administration for use in the pediatric population methotrexate), and biological DMARD therapies (e.g., anti-tumor necrosis factor-alpha [TNFa] agents, inhibitors of T-cell co-stimulation) [77] . Few clinical trials of biologic therapies in JIA have reported efficacy of the study drug in the control of pain, and assessment of pain is not incorporated in the traditional outcome measures used in these clinical trials (e.g., the American College of Rheumatology pediatric 30 response criteria.) [78] . Nevertheless, the available data suggests that these medications have the potential to reduce pain outcomes. In a study by Cespedes-Cruz et al. [79] , 521 patients with polyarticular JIA treated with methotrexate for 6 months showed significant improvement in pain intensity, physical function, and ability to participate in activities. Similarly, Prince et al. [80] followed 53 JIA patients treated with etanercept over a 27-month period and found a reduction in pain VAS (100-mm scale) from 55.6 to 12.4 mm and improvement in wellbeing VAS (100-mm scale) from 51.6 to 15.8 mm.
Abatacept has also been shown to improve all aspects of HRQL, including pain level and participation in activities [81] . Recently, investigators from Denmark evaluated the pain experienced by JIA patients treated with non-biologic treatments compared with those on anti-TNF agents [57] . They found that disease activity level was lower in the anti-TNF group. However, on average, reported pain intensity was the same in both groups. Although more children in the anti-TNF group reported no pain, a similar percentage of children in each group (24-29 %) reported pain on every day of the study period. Among children who reported pain, the intensity was greater in the anti-TNF group. A commentary on this report [58] highlights that the nonbiologic group consisted of a higher proportion of persistent oligoarticular patients (i.e., less severe disease), and they were twice as likely to receive NSAIDs, which may lead to better pain control. The study did not account for irreversible structural joint damage, which could lead to increased pain. Nonetheless, this study draws attention to the issue of persistent pain in a significant proportion of children treated with biological agents, even when good disease control is achieved. In addition to pharmacological therapies that aim to reduce arthritis disease activity, medications specifically targeting pain reduction should be considered for JIA patients with persistent pain. The World Health Organization's (WHO) most recent guidelines for the pharmacological treatment of persisting pain in children with medical illnesses recommend using a two-step strategy, dosing at regular intervals, using the appropriate route of administration, and adapting treatment to the individual [59] . The first step, for the treatment of mild pain, combines NSAIDs (Table 2 ) and acetaminophen (10-15 mg/kg every 4-6 h; max 1 g/dose 9 4 doses/day) as the medications of choice. Adjunctive treatment with topical NSAIDs such as diclofenac 2 % solution or 1 % gel to painful areas may be helpful. Although there are no studies specifically in the pediatric population, significant benefit has been reported in adult patients with chronic musculoskeletal pain [56] . For patients with moderate to severe pain, the use of low doses of strong opioid analgesics should be considered [59, 73, 82] . The WHO recommends morphine as the opioid of choice, and discourages the use of codeine due to problems with safety and efficacy [59] . If analgesia is inadequate and/ or there are dose-limiting side effects, other options include hydromorphone, methadone and oxycodone (Table 3) . Tramadol is a weak opioid that has been used in adults with moderate pain; however, effectiveness and safety studies in children are lacking [59] .
There is limited research on the use of opioids in childhood arthritis, and one survey found that 60 % of pediatric rheumatologists disagree with the use of opioid analgesics for the treatment of persistent pain due to concerns for side effects and addiction [9] . However, as pointed out by Connelly and Schanberg [83] , many of these concerns are unfounded. Kimura et al. [9] suggest that, ''if conventional anti-arthritis agents are utilized to an optimal degree but pain persists, it may be more prudent to utilize analgesic medications than it would be to increase the intensity (and possible toxicity) of the treatment regimens''. Consultation with a specialized chronic pain team should be considered for patients with refractory pain.
Behavioral and Rehabilitative Treatments for Pain
Evidence-based psychological interventions (e.g., relaxation strategies, parent interventions, cognitive behavioral therapies or CBT) should be recommended for JIA patients with chronic pain [84] . A recent Cochrane review of pain interventions found relaxation and CBT to be effective in reducing pain intensity and disability in children with chronic pain [85] . CBT strategies in JIA patients include normalization of the patient's experience through education on the disease and its impact on daily activities, training in specific coping strategies, managing diseaserelated and other stressors, and providing guidance on developing and implementing a long-term plan for selfmanaging the condition [86] . Although CBT helps patients to become more self-reliant and promotes better pain coping strategies, it is also important to teach parents adaptive responses to their child's pain to strengthen rehabilitation efforts [37] . Children whose parents participated in psychological therapies and CBT had improvement in their pain symptoms [37] . Sleep hygiene should be reviewed with JIA patients as they often suffer from poor sleep (including delayed sleep onset, discontinuous sleep, nap behavior) secondary to pain and stiffness, and improved quality of sleep often lessens pain and fatigue.
Physical and occupational therapy helps to improve strength and function, range of motion, and to reduce pain in JIA patients [37] . A regular exercise routine reduces pain, fatigue, and disability and improves quality of life [87] . In addition, regular exercise promotes healthy living by limiting weight gain, boosting bone health, and fostering peer interaction. The use of fitted foot orthoses in JIA patients with lower extremity involvement has shown statistically significant improvement in pain VAS and HRQL after 3 months of use [88] .
Studies have shown that JIA patients commonly use complementary and alternative medicine (CAM) such as herbal supplements, and mind and body practices such as chiropractic, massage, and meditation [89, 90] . These issues bring to light the importance of asking patients about the use of CAM therapies to ensure that there are no medication interactions or side effects and to aid in proper coordination of care.
Conclusions
It is critically important for clinicians to recognize that pain is the most common and distressing symptom of JIA. Therefore, the frequent and consistent assessment of pain using valid, reliable, and age-appropriate tools should form a cornerstone of disease management. Given that many patients will continue to experience pain despite adequate pharmacological treatment, clinicians should incorporate other pain management modalities, such as physical and psychological therapies, into their practice. Despite the progress that has been made in the field of pain in JIA, there is an urgent need to better understand the neurobiological pain processing mechanisms in the central nervous system that persist following the resolution of the inflammatory component of JIA. It is likely that current therapies do not address or target these changes. However, to date, there have been no clinical trials to directly evaluate the effectiveness of different pain medications for alleviating pain in JIA. In the context of the biopsychosocial model, future work is also needed to better understand the impact of factors such as mood, anxiety, and pain coping in the maintenance of JIA pain. 
